GeoVax Labs Inc. (GOVX.OB) Opens Second Clinical Trial Site for HIV Vaccine
Today, GeoVax Labs, Inc. announced that it has opened a second clinical trial site at the Alabama Vaccine Research Clinic (AVRC) of the University of Alabama at Birmingham (UAB) to expand the company's HIV therapeutic vaccine trial. This trial marks the first clinical trial that uses the same products for treatment of persons who already have the HIV infection. The study will last up to 77 weeks for each participant. To be eligible, volunteers need to be diagnosed within the first year of HIV infection and they must have started antiretroviral drug therapy within six months of diagnosis. Researchers will…